Total Funding
10
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
1104509
OncoMed Pharmaceuticals is a biotechnology company developing novel therapeutics for the treatment of cancer.
Acquired by 
Mereo Biopharma
Jakob Dupont: Senior Vice President, Chief Medical OfficerPast Role: Memorial Sloan - Kettering Cancer Center, Faculty Appointment
About the Company
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells“. They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics
that could provide important alternatives for the treatment of cancer.
